Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico

Background: Ten to fifteen percent of patients with myasthenia gravis (MG) have treatment-refractory disease. In short series and case reports, rituximab has proven to be effective in refractory MG. Methods: A retrospective, longitudinal study was conducted. Recruitment was performed in an MG cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Hernández, Juan Carlos, Galnares-Olalde, Javier A, Gómez-Figueroa, Enrique, Jorge de Sarachaga, Adib, Vargas-Cañas, Edwin Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946608/
https://www.ncbi.nlm.nih.gov/pubmed/33728176
http://dx.doi.org/10.7759/cureus.13226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946608/
https://www.ncbi.nlm.nih.gov/pubmed/33728176
http://dx.doi.org/10.7759/cureus.13226

Ejemplares similares